Posted by cassandracomplex on May 23, 2013, at 14:31:37
In reply to Re: Experimental AD Moves Closer To Approval, posted by SLS on May 21, 2013, at 18:48:29
> Vortioxetine is quite a bit different from other SSRIs. I think it deserves to be treated seriously as a potential treatment. For each new drug that becomes available, a certain percentage of previously treatment-resistant patients will go on to respond to it.
>
>
> - Scott
>
> =======================================
>
> Dual mechanism of action
>
> Vortioxetine displays two complementary mechanisms of action in vitro: inhibition of serotonin reuptake and modulation of serotonin receptor activity. In addition to blocking the serotonin transporter protein, vortioxetine acts as antagonist at 5-HT3 and 5-HT7 receptors, a partial agonist at 5-HT1B receptors and an agonist at 5-HT1A
>
> =======================================
>
>I suppose I feel like too many members in the psychiatric community has embraced serotonergic drugs and the "serotonin hypothesis" that other potential drugs that work on different neurotransmitters are being neglected. And that too many treatment-resistant patients are prescribed these "hot new medications," only to fail to respond to them, after trying every SSRI and SNRI on the market (often with various augmentation strategies), before they're ever offered a TCA or MAOI.
I admit that I'm biased because, having been on nearly every antidepressant on the market and having had ECT, I appear to be a "Parnate-Specific Patient" (as one paper in a psychiatric journal is entitled).
poster:cassandracomplex
thread:1044014
URL: http://www.dr-bob.org/babble/20130501/msgs/1044138.html